Chemotherapy for androgen-independent prostate cancer

World Journal of Urology

Volumn 23, Issue 1, 2005, Pages 10-13

  Petrylak, Daniel P ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Androgen independent prostate cancer; Chemotherapy

Indexed keywords

ACETYLSALICYLIC ACID; ANDROGEN; BEVACIZUMAB; BORTEZOMIB; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; THALIDOMIDE; VINBLASTINE; WARFARIN;

ALOPECIA; ANDROGEN THERAPY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PAIN; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG FATALITY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HEART MUSCLE ISCHEMIA; HUMAN; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; PERIPHERAL EDEMA; PROSTATE CANCER; RISK REDUCTION; VASCULAR DISEASE; VOMITING;

ANDROGENS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 15844376655     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-004-0482-0     Document Type: Article

References (29)

1. Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71[Suppl]:1098-1109
2. Kantoff PW, Halabi S, Conaway M et al. (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 17:2506-2513
3. Tannock IF, Osoba D, Stockler MR et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764
4. Petrylak DP, Tangen CM, Hussain MH et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 351:1513-1520 10.1056/ NEJMoa041318
5. Tannock IF, De Wit R, Berry WR et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 351:1502-1512 10.1056/NEJMoa040720
6. Catz SD, Johnson JL (2003) BCL-2 in prostate cancer: A minireview. Apoptosis 8:29-37 10.1023/A:1021692801278
7. Haldar S, Chintapalli J, Croce CM (1996) Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56:1253-1255
8. Dahllof B, Billstrom A, Cabral F, Hartley-Asp B (1993) Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 53:4573-4581
9. Pienta KJ, Lehr JE (1993). Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix. J Urol 149:1622-1625
10. Speicher LA, Barone LR, Chapman AE et al. (1994) P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst 86:688-694 10.1023/A:1021692801278
11. Perry CM, McTavish D (1995) Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 7:49-74
12. Tew KD, Glusker JP, Hartley-Asp B, Hudes G, Speicher LA (1992) Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmacol Ther 56:323-339 10.1016/0163-7258(92)90023-S
13. Speicher LA, Barone L, Tew KD (1992) Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 52:4433-4440
14. Kreis W, Budman DR, Calabro A (1997) Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 79:196-202
15. Hudes G, Einhorn L, Ross E et al. (1999) Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 17:3160-3166
16. Berry WR, Hathorn JW, Dakhil SR et al. (2004) Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin Prostate Cancer 3:104-111
17. Picus J, Schultz M (1999) Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results. Semin Oncol 26 [Suppl 17]:14-18
18. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ (1993) Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 72:2457-2460
19. Beer TM, Pierce WC, Lowe BA, Henner WD (2001) Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12:1273-1279 10.1023/A:1012258723075
20. Berry W, Dakhil S, Gregurich MA, Asmar L (2001) Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28 [Suppl 15]:8-15
21. Trivedi C, Redman B, Flaherty LE et al. (2000) Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 89:431-436 10.1002/ 1097-0142(20000715)89:2<431::AID-CNCR31>3.0.CO;2-B
22. Obasaju C, Hudes GR (2001) Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am 15:525-545
23. Petrylak DP, Macarthur RB, O'Connor J et al. (1999) Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17:958-967
24. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V (1999) Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33-38 1:STN:280:DyaK1M7ns1Sitw%3D%3D
25. Petrylak DP, Macarthur R, O'Connor J et al. (1999) Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 26 [Suppl 17]:28-33
26. Savarese DM, Halabi S, Hars V et al. (2001) Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 19:2509-2516
27. Dahut WL, Gulley JL, Arlen PM et al. (2004) Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22:2532-2539 10.1200/JCO.2004.05.074
28. Picus J, Halabi S, Rini B et al. (2003) The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006. Proceeding of the American Society of Clinical Oncology, 2003, 22:393
29. Dreicer R, Roth B, Petrylak D et al. (2004) Phase I/II trial of bortezomid plus docetaxel in patients with advanced androgen-independent prostate cancer. Proceeding of the American Society of Clinical Oncology, 2004, 22:4664